Posted in | Nanobusiness

NanoGuardian Enters into Partnership with Altegrity Risk International

Published on April 6, 2010 at 7:48 PM

NanoGuardian™ announced today that it entered into a partnership with Altegrity Risk InternationalSM (ARI) to serve as NanoGuardian's security partner in delivering its Closed-Loop Protection™ Program, which assists manufacturers in detecting counterfeit and illegally diverted products in the legitimate supply chain.

NanoGuardian's Closed-Loop Protection Program works hand-in-hand with its NanoEncryption™ technology and utilizes statistical modeling with randomized pharmacy auditing in an effort to identify counterfeit or illegally diverted pharmaceuticals on pharmacies' shelves awaiting distribution to patients. The mission of NanoGuardian's Closed-Loop Protection Program is to provide early detection of counterfeit and illegally diverted products, helping to reduce risk to patients, brands, and companies.

“NanoGuardian is committed to forging relationships with best-of-class partners in our effort to protect patients and brands. We are very excited to announce another such partnership with ARI, a global leader in corporate security with significant experience in the pharmaceutical space,” said Dean Hart, executive vice president, NanoGuardian. “Pharmaceutical counterfeiting and diversion are growing concerns throughout the world, and the criminals engaged in these activities are sophisticated and well-resourced. On-dose security technologies, such as NanoGuardian's NanoEncryption technology, that remain with every dose indefinitely and defy counterfeit packaging, are absolutely necessary to protect patients and brands in this escalating war. Programs such as NanoGuardian's Closed-Loop Protection that proactively search for the emergence of counterfeit and illegally diverted medications in the legitimate supply chain provide an additional measure of protection and safety while reducing risks to patients, brands, and companies. ARI's experience and the depth and breadth of its resources are great additions to the NanoGuardian solution,” added Hart.

“We are thrilled to partner with NanoGuardian in its efforts to protect patients by ensuring supply chain integrity,” said Thomas McWeeney, Managing Director & Head of the Washington D.C. Office, ARI. “ARI's industry-leading expertise and experience in security consulting, investigative intelligence, and monitoring services make this partnership ideal given the cutting-edge protection that NanoGuardian's NanoEncryption technology provides pharmaceutical manufacturers. ARI will leverage our diverse resources—including more than 2,800 cleared investigators located throughout the United States and U.S. territories as well as our network of professionals around the globe with experience in more than 150 countries—to ensure the chain of custody of pharmaceutical products that are acquired as a part of the Closed-Loop Protection Program. Given its NanoEncryption technology with the Closed-Loop Protection market monitoring program, NanoGuardian has proven that it is at the forefront of brand protection for the pharmaceutical industry.”

NanoGuardian's NanoEncryption fights both counterfeiting and illegal diversion with a single technology that works directly on capsules, tablets, vial caps, and single-use syringes to provide an intrinsic, layered security strategy of overt, covert, and forensic security features. The overt and covert security features allow dose-level authentication at any point in a manufacturer's supply chain, while the forensic and nano-scale NanoCodes™ provide comprehensive tracing information on each and every dose. NanoGuardian's technology provides a strong benefit over other on-dose technologies given that NanoGuardian's security features are implemented with no additional chemicals being added to the medication.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit